Novel antipsychotic drugs
著者
書誌事項
Novel antipsychotic drugs
Raven Press, c1992
大学図書館所蔵 全2件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
This volume contains the highlights of an American College of Neuropsychopharmacology conference on new directions in the development of a typical and other novel antipsychotic drugs. An international group of psychiatrists from leading medical centres and researchers from universities and the pharmaceutical industry presents new theories and preclinical and clinical data on various drugs and classes of drugs, including amperozide and other clozapine-type drugs, substituted benzamides, dopamine partial agonists, dopamine autoreceptor agonists. D1, D3 and D4 antagonists, milacemide, glycine, sigma antagonists, and 5-HT3 antagonists. The contributors develop concepts on the receptor selectivities and mechanisms of action of a typical neuroleptics and identify various receptors and neurochemical mechanisms as new targets for antipsychotic drugs. The book includes a clinical overview of risperidone and discussions on the pattern of efficacy of clozapine in treatment resistant schizophrenia, the mechanism of action of clozapine in relation to its clinical advantages, and the efficacy and tolerability of novel dopamine agonists.
目次
- Part 1 Clozapine type atypical antipsychotic drugs: the mechanism of action of clozapine in relation to its clinical advantages, Herbert Y. Meltzer
- Org 5222 - preliminary clinical results, J.M. Ad Sitsen and Maria C. Vrijmoed-de Vries
- amperozide and some other atypical compounds with antipsychotic effect, Erick G.G. Christensson
- clozapine - pattern of efficacy in treatment-resistant schizophrenia, Herbert Y. Meltzer
- amperozide in the treatment of schizophrenic patients - a preliminary report, Anders Bjork, et al. Part 2 Substituted benzamides: comparison of the effects of different substituted benzamides on depamine receptor function in the rat, Sven O. Ogren and M. Hall
- remoxipride and raclopride - pharmacological background and clinical outcome, Tommy Lewander, et al. Part 3 Dopamine agonists: effects of PD 128483, a novel dopamine autoreceptor agonist, in preclinical antipsychotic tests, Thomas G. Heffner, et al
- novel dopamine autoreceptor agonists B-HT 920 and EMD 49980 in the treatment of patients with schizophrenia, Klaus Wiedemann, et al
- efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia, Dieter Naber, et al
- the status of "Second Generation" selective D. dopamine receptor antagonists as putative atypical antipsychotics, John L. Waddington and Siobhan A. Daly
- toward the understanding of the neuroanatomical substrate of schizophrenia - the contribution of savoxepine, Serge F. Bischoff
- the dopamine D3 receptor as a target for antipsychotics, Jean-Charles Schwartz, et al
- receptor selectivities of a typical neuroleptics, Philip Seeman. Part 4 Other approaches: glutamatergic mechanisms in neuropsychiatry, John W. Olney
- enhancement of NMDA-mediated transmission in schizophrenia - effects of milacemide, Carol A. Tamminga, et al
- glycine in the treatment of schizophrenia - theory and preliminary results, Steven G. Potkin, et al
- sigma "antagonists" - potential antipsychotics?, Duncan P. Taylor and R. Francis Schelemmer, Jr
- clinical efficacy of sigma antagonists in schizophrenia, Richard L. Borison, et al
- antipsychotic potential of 5-Ht3 antagonists in schizophrenia, Richard L. Borison, et al
- antipsychotic potential of 5-HT3 antagonists - preclinical data, Michael G. Palfreyman, et al
- the effects of a novel 5-HT3 antagonist, ondansetron, in schizophrenia - results from uncontrolled trials, Joseph DeVeaugh-Geiss, et al
- clinical overview of resperidone, Richard L. Borison, et al
- what makes a neuroleptic atypical, Daniel E. Casey.
「Nielsen BookData」 より